



Form PTO-1449 (modified)		Atty. Docket No. UTXC:561USC1	Serial No. 10/673,671
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant K. Jagannadha Sastry <i>et al.</i>	
		Filing Date: September 29, 2003	Group: Unknown
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 2	Other Art See Page 2	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
JS	C64	Roos <i>et al.</i> , "T cell function in vitro is an independent progression marker for AIDS in human immunodeficiency virus-infected asymptomatic subjects," <i>J. Infect. Dis.</i> , 171:531-536, 1995.
	C65	Rosenberg <i>et al.</i> , <i>Science</i> , "Vigorous HIV-1-specific CD4 ⁺ T cell responses associated with control of viremia," 278:1447-1450, 1997.
	C66	Rowland-Jones <i>et al.</i> , "HIV-specific cytotoxic T-cell activity in an HIV-exposed but uninfected infant," <i>Lancet</i> , 341:860-861, 1993.
	C67	Rowland-Jones <i>et al.</i> , "HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women," <i>Nature Med.</i> , 1:59-64, 1995.
	C68	Sarkar <i>et al.</i> , "Studies on <i>in vivo</i> induction of cytotoxic T lymphocyte responses by synthetic peptides from E6 and E7 oncoproteins of human papillomavirus type 16," <i>Viral Imm.</i> , 8:165-174, 1995.
	C69	Sastry and Arlinghaus, "Identification of T-cell epitopes without B-cell activity in the first and second conserved regions of the HIV Env protein," <i>AIDS</i> , 5:699-707, 1991.
	C70	Sastry <i>et al.</i> , "Rapid <i>in vivo</i> induction of HIV-specific CD8 ⁺ cytotoxic T lymphocytes by a 15-amino acid unmodified free peptide from the immunodominant V3-loop of GP120," <i>Virology</i> , 188:502-509, 1992.
	C71	Schendel <i>et al.</i> , "Cytotoxic T lymphocytes show HLA-C-restricted recognition of EBV-bearing cells and allorecognition of HLA class I molecules presenting self-peptides," <i>J. Immunol.</i> , 149:2406-2416, 1992.
	C72	Schrfer <i>et al.</i> , "T cell recognition of HIV synthetic peptides in a natural infection," <i>J. Immunol.</i> , 142:1166-1176, 1989, <i>NFK</i>
	C73	Sedegah <i>et al.</i> , "Protection against malaria by immunization with plasmid DNA encoding circumsporozoite protein," <i>Immunology</i> , 91:9866-9870, 1994.
	C74	Takahashi <i>et al.</i> , Specific lysis of human immunodeficiency virus type 1-infected cells by a HLC-A3.1-restricted CD8 ⁺ cytotoxic T-lymphocyte clone that recognizes a conserved peptide sequence within the gp41 subunit of the envelope protein," <i>Proc. Natl. Acad. Sci. USA</i> , 88:10277-10281, 1991.

EXAMINER: /Jeffrey Stucker/	DATE CONSIDERED: 06/15/2006
EXAMINER: INITIAL IF REFERENCE CONSIDERED; WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)



Form PTO-1449 (modified)		Atty. Docket No. UTXC:561USC1	Serial No. 10/673,671
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant K. Jagannadha Sastry <i>et al.</i>	
		Filing Date: September 29, 2003	Group: Unknown
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 2	Other Art See Page 2	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
JS	C20	Del Guercio <i>et al.</i> , "Potent immunogenic short linear peptide constructs composed of B cell epitopes and Pan DR T helper epitopes (PADRE) for antibody responses <i>in vivo</i> ," <i>Vaccine</i> 15:441-448, 1997.
	C21	Deres <i>et al.</i> , "In vivo priming of virus specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine," <i>Nature</i> , 342:561-564, 1989.
	C22	Dupuis <i>et al.</i> , "Characterization of HLA-A*0201-restricted cytotoxic T cell epitopes in conserved regions of the HIV type 1 gp160 protein," <i>J. Immunol.</i> , 155:2232-2239, 1995.
	C23	Falk <i>et al.</i> , "Allele-specific peptide ligand motifs of HLA-C molecules," <i>Proc. Nat'l Acad. Sci. USA</i> , 90:12005-12009, 1993.
	C24	Falk <i>et al.</i>, "Allele-specific peptide ligand motifs of HLA-C molecules," <i>Proc. Nat'l Acad. Sci. USA</i>, 90:12005-12009, 1993. Duplicate of C23
JS	C25	Falk <i>et al.</i> , "Expression of HLA-C molecules confers target cell resistance to some non-major histocompatibility complex-restricted T cells in a manner analogous to allospecific natural killer cells," <i>J. Exp. Med.</i> , 182:1005-1018, 1995.
	C26	Ferguson <i>et al.</i> , "Amino-acid residues involved in biological functions of the cytolytic enterotoxin from <i>Aeromonas hydrophila</i> ," <i>Gene</i> 156:79-83, 1995.
	C27	Ferguson <i>et al.</i> , "Hyperproduction, purification, and mechanism of action of the cytotoxic enterotoxin produced by <i>Aeromonas hydrophila</i> ," <i>Infect. Immun.</i> 65:4299-4308, 1997.
	C28	Flotte <i>et al.</i> , "An improved system for packaging recombinant adeno-associated virus vectors capable of <i>in vivo</i> transduction," <i>Gene Therapy</i> , 2:29-37, 1995.
	C29	Fuller and Haynes, "A qualitative progression in HIV type 1 glycoprotein 120-specific cytotoxic cellular and humoral immune responses in mice receiving a DNA-based glycoprotein 120 vaccine," <i>AIDS Res. Hum. Retroviruses</i> , 11:1433-1441, 1994.
	C30	Gallichan and Rosenthal, "Long-lived cytotoxic T lymphocyte memory in mucosal tissues after mucosal but not systemic immunization," <i>J. Exp. Med.</i> 181:1879-1890, 1996.
	C31	Gao <i>et al.</i> , "Priming of influenza virus-specific cytotoxic T lymphocytes <i>vivo</i> by short synthetic peptides," <i>J. Immun.</i> , 147(10):3268-3273, 1991.

EXAMINER: /Jeffrey Stucker/

DATE CONSIDERED: 06/15/2006

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)